← Back to Clinical Trials
Recruiting NCT06424509

NCT06424509 Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06424509
Status Recruiting
Phase
Sponsor Lund University
Condition Borderline Personality Disorder
Study Type OBSERVATIONAL
Enrollment 390 participants
Start Date 2010-01-01
Primary Completion 2026-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
High degree of long (>5 days) and/or compulsory psychiatric inpatient care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 390 participants in total. It began in 2010-01-01 with a primary completion date of 2026-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The current study aims to evaluate the impact of long (\>5 days) and/or compulsory psychiatric inpatient care on subsequent healthcare utilization for self-harm and suicide in people with borderline personality disorder, a condition characterized by frequent self-harm. The basis for this study is the diversity of clinical practices across Swedish regions. By categorizing clinics based on their practices with respect to long and/or compulsory psychiatric inpatient care, it is possible to explore the impact of these practices on subsequent somatic and psychiatric healthcare, including emergency care due to self-harm as well as on completed suicides. All psychiatric clinics across Sweden authorized to administer compulsory care for adults, totalling 78 clinics will be included. Each clinic per specific calendar year will represent one participant, identified by the clinic's name and the respective year (e.g., Umeå2010, Linköping2013, Malmö2022). Data collection will involve the utilization of the national registers to capture outcome measures and account for confounding factors. The participants will be ranked based on a composite variable, which includes the average number of days spent in inpatient compulsory care and other psychiatric inpatient care exceeding 5 days, among individuals diagnosed with BPD. The top quartile of participants will be compared with the bottom quartile.

Eligibility Criteria

Inclusion Criteria: * Psychiatric clinic in Sweden authorized to administer compulsory care for adults. Each clinic per specific calendar year will represent one participant, identified by the clinic's name and the respective year (e.g., Umeå2010, Linköping2013, Malmö2022). Exclusion Criteria: * No authorization to administer compulsory care for adults

Contact & Investigator

Central Contact

Sofie Westling, MD, PhD

✉ sofie.westling@med.lu.se

📞 +46735626099

Principal Investigator

Sofie Westling, MD, PhD

PRINCIPAL INVESTIGATOR

Lund University

Frequently Asked Questions

Who can join the NCT06424509 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Borderline Personality Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06424509 currently recruiting?

Yes, NCT06424509 is actively recruiting participants. Contact the research team at sofie.westling@med.lu.se for enrollment information.

Where is the NCT06424509 trial being conducted?

This trial is being conducted at Lund, Sweden.

Who is sponsoring the NCT06424509 clinical trial?

NCT06424509 is sponsored by Lund University. The principal investigator is Sofie Westling, MD, PhD at Lund University. The trial plans to enroll 390 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology